PVAC PROMOTES mRNA VACCINE TECHNOLOGY TRANSFER FOR LOCAL MANUFACTURING
The Public Vaccine Access Centre (PVAC) is promoting technology transfer initiatives aimed at strengthening local vaccine manufacturing capacity through the adoption of messenger RNA (mRNA) vaccine technology.
The initiative seeks to support the development of domestic vaccine production capabilities, reduce dependence on imported vaccines, and improve access to essential vaccines during public health emergencies.
mRNA vaccine technology gained global attention during the COVID-19 pandemic because of its potential to accelerate vaccine development and enable rapid responses to emerging infectious diseases. The technology provides instructions that enable the body’s cells to produce a specific protein, helping the immune system recognise and respond to a targeted pathogen.
Through technology transfer, local manufacturers can gain access to the technical knowledge, production processes, and expertise required to develop and manufacture vaccines within their own countries. This can also help strengthen scientific research, build local expertise, and improve the resilience of national healthcare systems.
For Nigeria and other African countries, expanding local vaccine manufacturing could help address challenges associated with dependence on foreign suppliers, international supply chain disruptions, and delays in obtaining vaccines during disease outbreaks.
However, achieving sustainable local production will require significant investment in manufacturing facilities, research and development, workforce training, regulatory oversight, and quality-control systems. Collaboration among governments, research institutions, pharmaceutical companies, and international health organisations will also be important.
The promotion of mRNA technology transfer represents an opportunity to strengthen health security, encourage innovation, and create jobs within the biotechnology and pharmaceutical sectors.
If successfully implemented, the initiative could contribute to a more self-reliant vaccine manufacturing industry, improve preparedness for future pandemics, and support broader efforts to expand equitable access to vaccines across Africa.
